Prograf Antitrust MDL Lawyers Seek $34M In Fees
Attorneys for certain buyers of organ transplant anti-rejection drug Prograf sought $34 million in fees and expenses Thursday, three months after reaching a $98 million deal with Astellas Pharma US Inc....To view the full article, register now.
Already a subscriber? Click here to view full article